Zosano Pharma Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-23: Form 8-K; Period of report 2019-12-23; Description 8.01 Other Events; Details 8.01.
- 2019-11-27: Form 8-K; Period of report 2019-11-27; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2019-11-14: Form 8-K; Period of report 2019-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-10-24: Form 8-K; Period of report 2019-10-24; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-23 | 8-K | 2019-12-23 | 8.01 Other Events | 8.01 On December 23, 2019, Zosano Pharma Corporation (the “Company”) announced the submission of a 505(b)(2) New Drug Application (“NDA”) for QtryptaTM to the U.S. Food and Drug Administration (“FDA”) for the acute treatment of migraine. | d855699d8k.htm |
| 2019-11-27 | 8-K | 2019-11-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d834858d8k.htm |
| 2019-11-14 | 8-K | 2019-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2019, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | earningspressrelease8k.htm |
| 2019-10-24 | 8-K | 2019-10-24 | 8.01 Other Events | 8.01 On October 24, 2019, Zosano Pharma Corporation (the “Company”) announced that the Company has begun enrolling cluster headache patients in the ATAC clinical trial. | clinicalstudy.htm |
| 2019-10-10 | 8-K | 2019-10-10 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously disclosed, on October 7, 2019, Zosano Pharma Corporation (the “Company”) informed The Nasdaq Stock Market LLC (“Nasdaq”) that as a result of Troy Wilson’s resignation from the Company’s Board of Directors (the “Board”) and the Audit Committee of the Board (the “Audit Committee”), effective October 5, 2019, the Company was not in compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Company’s Audit Committee to be composed of at least three independent directors. | d818296d8k.htm |
| 2019-10-08 | 8-K | 2019-10-05 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 3.01 On October 7, 2019, Zosano Pharma Corporation (the “Company”) informed The Nasdaq Stock Market LLC (“Nasdaq”) that as a result of Troy Wilson’s resignation from the Company’s Board of Directors (the “Board”) and the Audit Committee, effective October 5, 2019, as is described further in Item 5.02 of this Current Report on Form 8-K, the Company was no longer in compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Company’s Audit Committee to be composed of at least three independent directors. 5.02 On October 5, 2019, John P. Walker, the President and Chief Executive Officer of the Company, notified the Company of his intent to resign, to be effective on the date the Company’s new President and Chief Executive Officer, Steven Lo, commences his employment with the Company, which is expected to be October 21, 2019. | d38016d8k.htm |
| 2019-09-27 | 8-K | 2019-09-27 | 8.01 Other Events | 8.01 On September 27, 2019, Zosano Pharma Corporation (the “Company”) issued a press release announcing an inducement grant under Nasdaq Listing Rule 5635(c)(4), which was approved by the Board of Directors of the Company on September 25, 2019. | a8kinducementgrant.htm |
| 2019-09-10 | 8-K | 2019-09-09 | 8.01 Other Events | 8.01 On September 9, 2019, Zosano Pharma Corporation (the “Company”) announced an oral presentation and two poster presentations of positive data from a one-year long-term safety study of Qtrypta™ (M207) for the acute treatment of migraine were presented at the 19th Congress of the International Headache Society (“IHC”) in Dublin, Ireland. | qtrypta.htm |
| 2019-08-26 | 8-K | 2019-08-26 | 1.02 Termination of a Material Definitive Agreement | 1.02 As previously disclosed, on October 20, 2017, Zosano Pharma Corporation (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) providing for the purchase by Lincoln Park of up to $35.0 million worth of the Company’s common stock over the term of the Purchase Agreement. | a8-keloc.htm |
| 2019-08-19 | 8-K | 2019-08-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d764477d8k.htm |
| 2019-08-14 | 8-K | 2019-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2019, we issued a press release titled “Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update”. | q2fy198k.htm |
| 2019-07-22 | 8-K | 2019-07-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On July 18, 2019, Zosano Pharma Corporation (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”). | d770063d8k.htm |
| 2019-05-31 | 8-K | 2019-05-25 | 4.01 Changes in Registrant's Certifying Accountant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 4.01 On May 28, 2019, Zosano Pharma Corporation, a Delaware corporation (the “Company”), dismissed Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm. 5.02 On May 25, 2019, the compensation committee of the board of directors of the Company approved bonus payments to each of the Company’s named executive officers in respect of fiscal 2018. | d757960d8k.htm |
| 2019-05-14 | 8-K | 2019-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2019, we issued a press release titled “Zosano Pharma Reports First Quarter 2019 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | q1fy198k.htm |
| 2019-04-11 | 8-K | 2019-04-09 | 8.01 Other Events | 8.01 On April 9, 2019, Zosano Pharma Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), pursuant to which the Company agreed to issue and sell 5,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Underwriter (the “Offering”). | d725709d8k.htm |
| 2019-03-14 | 8-K | 2019-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2019, we issued a press released titled “Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | q4fy188k.htm |
| 2019-02-28 | 8-K/A | 2019-01-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As reported in the Original Filing, on January 14, 2019, the Board of Directors (the “Board”) of the Company appointed Linda Grais, M.D., J.D., as a member of the Board. | d715509d8ka.htm |
| 2019-01-16 | 8-K | 2019-01-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 14, 2019, the Board of Directors of Zosano Pharma Corporation (the “Company”) appointed Linda Grais M.D., J.D., effective immediately, to serve as a member of the Board. | d691028d8k.htm |